Enter the first few characters of Company and click 'Go'

Gujarat Themis Biosyn Ltd. Company History and Annual Growth Details

Gujarat Themis Biosyn Ltd. was incorporated in 1981 jointly by GIIC and chemosyn (P) Ltd. GIBL commenced production in Aug.1985 by producing antibiotic erythromycin, and erythromycin salts and formulations. GTBL was a sick company which was forced to discontinue production because of accumulated losses. The company was takenover during June 1991 by pharmaceutical Business Group India Ltd; a unique consortium of five competing drug companies - Themis Chemicals, Kopran, Anant & Co., Cadila and Lyka Labs. The company has technical and financial collaboration with Yuhan Corporation, South Korea. With Yuhan's knowhow, GTBL has become India's first company to start commercial production of anti-tubercolis drug, rifampicin.

2002-Gujarat Themis Biosyn Ltd has informed that Mr Rajneesh Anand has been appointed as the Managing Director of the Company w e f February 01, 2002.

2008

-Gujarat Themis Biosyn Ltd has appointed Mr. S S Lee as an Additional Director of the Company.

-The Company has appointed Mr. Rajneesh Anand as Managing Director

2010

- Gujarat Themis Biosyn Ltd has appointed Mr. Subhash C Kaushik as Additional Director of the Company.

2011

-The Board of Directors appointed Mr. Rajneesh Anand as Managing Director of the Company

2012

-The Company has received a Rehabilitation Scheme approved by the Board of Industrial and Financial Reconstruction (BIFR)

2014

-Mr. Vikas Tarekar has been appointed as a Company Secretary of the company.

-Mr. Tapas Guha has been appointed as a CEO of the Company.

2023

-The Company has splits its face value from Rs. 5/- to Rs. 1/-.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article